Kornimate/medical-research-clean huggingface dataset:
rtms efficacy coupled with mirror therapy

Conditions: Neuropathic Pain

Summary: neuropathic pain is particularly difficult to treat with classic first-line drugs. neuromodulation techniques using repetitive transcranial magnetic stimulation (rtms) are useful alternative, but there is a need to improve their analgesic effect.virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rtms.the present project will investigate in individuals with neuropathic pain the effects of the rtms coupled with virtual reality mirror therapy.

this project introduces a new research question that incorporates virtual reality mirror therapy into an established treatment protocol of repetitive transcranial magnetic stimulation (rtms) for neuropathic pain relief. neuropathic pain is particularly difficult to treat with classic first-line drugs. neuromodulation techniques using repetitive transcranial magnetic stimulation (rtms) are useful alternative, but there is a need to improve their analgesic effect. virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rtms. the efficacy of using both techniques in neuropathic pain treatment is unknown. the present project will investigate in individuals with neuropathic pain the effects of the rtms coupled with virtual reality mirror therapy on: 1) daily pain intensity (i.e. analgesic efficacy); 2) other components of pain and the quality of life; 3) brain activity. it will be the first to provide insight into the efficacy of using together both non-invasive technics of cortical neuromodulation to alleviate pain.

Eligibility criteria:
inclusion criteria: * clinical symptoms typical of neuropathic pain * refractory to drug therapies * lasting for at least 6 months, with a moderate to severe pain intensity (≥4/10 on visual analog scale, vas) and a stable pain treatment since 1month at least * having right to health benefits exclusion criteria: * ferromagnetic components and implanted microprocessors (i.e. cochlear implants) * drug-resistant or active epilepsy, pacemaker, pregnancy, ongoing depression or personality troubles, and ongoing opioid treatment. * any other contraindications to mri scanner (e.g., claustrophobia, etc.).

Keywords: transcranial magnetic stimulation virtual reality mirror therapy brain networks predictive model
a study of trilaciclib combined with chemotherapy in the treatment of advanced nsclc with leptomeningeal metastasis

Conditions: NSCLC

Summary: to observe the efficacy of trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastasis。

a single-arm, open-label, interventional study was conducted in 25 nsclc patients with leptomeningeal metastases to observe the efficacy of trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastases, and to evaluate the incidence and duration of severe neutropenia in the first cycle.

Eligibility criteria:
inclusion criteria: * must be at least 18 years when fisrt dose of trilaciclib, regardless of gender； * ecog-ps score of 0-1，and no worsening in the 2 weeks before the study drug； * expected survival≥12 weeks； * advanced non-small cell lung cancer with leptomeningeal metastasis； * with an ommaya sac has been implanted； * at least one measurable lesion meeting recist1.1 criteria was present； * laboratory tests met the following criteria: hemoglobin ≥100 g/l (female), 110g/l (male) ；neutrophil count ≥ 2×109/l ；platelet count ≥100×109/l; creatinine ≤ 15mg/l or creatinine clearance (crcl) ≥ 60 ml/min (cockcroft-gault formula); total bilirubin ≤ 1.5× upper limit of normal value (uln); alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 3 × uln or 5× uln (for patients with liver metastases); albumin ≥ 30 g/l; * patients of reproductive age(including female and male patients'female companions)must use effective birth control measures; * voluntarily participate and sign informed consent; exclusion criteria: * patients of reproductive age(including female and male patients'female companions)must use effective birth control measures; * stroke or cardio-cerebrovascular event within 6 months before enrollment; * qtcf interval \> 480msec at screening, qtcf \> 500msec for patients with implanted ventricular pacemakers; * previous hematopoietic stem cell or bone marrow transplantation; * allergy to the study drug or its components; * if the investigator considers that it is not suitable to participate in this study.
a safety and efficacy study of golimumab (cnto 148) in patients with active rheumatoid arthritis despite methotrexate therapy

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite methotrexate therapy. another objective is to evaluate the pharmacokinetics of golimumab.

this clinical study is scheduled to be performed for the purpose of evaluating the safety and effectiveness of golimumab (cnto148) administered in combination with stable dose (6-8mg/week) of methotrexate (mtx) to patients with rheumatoid arthritis (ra). cnto148 50 mg group: cnto148 50 mg sc injections every 4 weeks from the first administration until week 152. if early escape, 100 mg sc injections every 4 weeks from week 16 until week 152. cnto148 100 mg group: cnto148 100 mg sc injections every 4 weeks from the first administration until week 152 whether early escape or not placebo group: placebo sc injections every 4 weeks from the first administration until week 20 and then cnto148 50mg sc injections every 4 weeks from week 16 until week 152

Eligibility criteria:
inclusion criteria: * patients diagnosed with rheumatoid arthritis at least 3 months prior to registration and who are definitely identified as having rheumatoid arthritis, at the time of informed consent, according to the criteria for classification established by the american college of rheumatology (1987) * patients in whom mtx therapy (\>= 6 mg/week) was started more than 3 months before the first administration and who have been treated with mtx at a stable dose (6-8 mg/week) for at least 4 weeks before the first administration * patients having at least 4 swollen joints and at least 4 tender joints at the time of registration and immediately before the first administration. exclusion criteria: * patients with a history of hypersensitivity to human immunoglobulin proteins or other ingredients of golimumab * patients who have previously experienced or are suffering from any of the following diseases: (i) collagen diseases other than rheumatoid arthritis, (ii) latent or active granulomatous infections such as histoplasmosis and coccidioidomycosis, (iii) felty syndrome, etc * patients with a severe, advanced, or poorly controlled disease in any of the kidney, liver, blood, gastrointestinal system, endocrine system, lung, heart, nervous system, psychiatric system, and brain.

Keywords: rheumatoid arthritis fully human anti-tnfa monoclonal antibody cnto148 golimumab
micrornas tool for stratifying stage ii colon cancer

Conditions: Colonic Neoplasms; Effects of Chemotherapy

Summary: the investigators discover the investigators' mirna tool can be a useful tool to predict the patients with stage ii colon who can benefit from chemotherapy.then the investigators plan to make an observation study that may validation this tool.

this is an observation study. the investigators recruit patients who agree to use their postoperative specimen for mirna tool examination and receive the investigators' follow up.their receiving chemotherapy or not will decided by their doctors. the investigators just see whether the stratifying tool could predict prognosis.

Eligibility criteria:
inclusion criteria: * the informed consent has been obtained from the patient. * with confirmed diagnosis of stage ii colon cancer. * with moderate/good ecog health rating (ps): 0-1 score. * the patient receive no anti-cancer treatment before primary surgery. * the patient receive radical operation for colon cancer with negative margin. exclusion criteria: * with severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. * with bad compliance or contraindication to enrollment. * pregnant woman or lactating woman. * with contraindication to receive adjuvant chemotherapy.
a study to evaluate the effectiveness of essure post-novasure radiofrequency endometrial ablation procedure following a successful essure confirmation test

Conditions: Contraception; Menorrhagia

Summary: the purpose of the post approval study is to evaluate the effectiveness and safety of the essure system when a novasure endometrial ablation procedure is performed following a successful essure confirmation test.

this study has previously been posted by conceptus, inc. after acquiring conceptus, inc., bayer is now the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * all inclusion criteria from the essure permanent birth control system instructions for use and/or the novasure impedance controlled endometrial ablation (ea) system instructions for use and controller operator's manual will apply. * women experiencing menorrhagia due to benign causes * women who are relying on the essure micro-inserts for permanent contraception following a successful essure confirmation test (as applicable to the post approval study) * women willing to accept the risk of pregnancy while relying on the essure micro-inserts for prevention of pregnancy following a novasure ablation procedure for menorrhagia exclusion criteria: * all exclusion criteria from the essure permanent birth control system instructions for use and/or the novasure impedance controlled endometrial ablation system instructions for use and controller operator's manual will apply. * women who previously underwent a fallopian tube sterilization procedure (other than essure placement) * women who present with any other medical complaints, conditions or symptoms unrelated to the essure system and/or subsequent novasure ea including, but not limited to: * gynecological co-morbidities (e.g., pelvic infection, cervicitis, undiagnosed vaginal bleeding, endometrial cancer, myomas, and polyps) * reproductive tract anatomical variants and/or pathology which could make the subject unsuitable for the essure and/or novasure transcervical procedures * women currently wearing an intrauterine device and unwilling to have it removed before novasure

Keywords: endometrial ablation permanent sterilization essure novasure prevention of pregnancy
a study to assess immunization responses in adult and adolescent participants with moderate-to-severe atopic dermatitis treated with nemolizumab

Conditions: Dermatitis, Atopic

Summary: the purpose of this study is to assess the effect of nemolizumab (cd14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (ad).

this is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent participants (≥ 12 to 54 years) with moderate-to-severe ad. eligible participants must have a documented history of inadequate response to topical ad medication(s). approximately 200 participants were randomized 1:1 to receive either 30 mg nemolizumab (with a 60 mg loading dose) or placebo, stratified by baseline disease severity investigator global assessment (iga) (iga = 3, moderate; iga = 4, severe). the study consisted of a 2- to 4-week screening period, a 16-week treatment period, and an 8-week follow-up period (12 weeks after the last study drug injection).

Eligibility criteria:
inclusion criteria: * chronic ad for at least 2 years * easi score \>= 16 * iga score \>= 3 * ad involvement \>= 10% of bsa * peak (maximum) pruritus nrs score of at least 4.0 exclusion criteria: * body weight \< 30 kilogram (kg) * history of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study drug excipients * history of severe allergic reaction to either vaccine or to vaccine components including alum, thimerosal, phenol * participants for whom administration of the meningococcal vaccine provided in this study is contraindicated or medically inadvisable * participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable * receipt of any vaccine (except inactivated influenza vaccine) within 12 weeks prior to screening, any meningococcal vaccine within 1 year prior to screening, or any tetanus-, diphtheria-, or pertussis-containing vaccine within 5 years prior to screening

Keywords: eczema ad vaccine nemolizumab pruritis itchy
cardiovascular risk profile among mexican-americans

Conditions: Cardiovascular Diseases; Atherosclerosis; Heart Diseases

Summary: to characterize the epidemiology and genetics of apolipoproteins a-i, a-ii, b, c-ii, c-iii, and e in a population of mexican-americans in starr county, texas.

background: evidence has established that the distribution and burden of several common chronic diseases among mexican-americans differ from that in the general population. these diseases include diabetes (almost exclusively noninsulin dependent diabetes), hypertension, and gallbladder disorders. while progress was made towards an elucidation of their epidemiology within this population, there was a paucity of data regarding other cardiovascular risk factors, most notably, the distribution of lipoproteins and their constituent apoproteins. with regard to the apolipoproteins, there were only minimal data from any population dealing with their distribution and relationships in the general population or pedigrees. this project provided as complete a profile on the distribution of metabolic cardiovascular risk factors as could be claimed for any other study of comparable size and provided baseline values for apo a-i, a-ii, b, c-ii, c-iii and e. design narrative: one thousand randomly selected individuals were given a complete physical examination. from those 1,000, 100 probands with gallbladder disease were selected. approximately 1,200 first degree relatives of the probands were invited to participate in the study and given a physical examination. additionally, 100 control individuals, their spouses and first degree relatives were followed longitudinally for five years. blood samples were obtained for determination of total cholesterol, ldl cholesterol, hdl2 and hdl3 cholesterol, and genetic markers. data were collected on age, sex, body mass and fat distribution, diet, smoking, and alcohol consumption. annual follow-up assessed the dynamics of changes in apolipoprotein levels and profiles and those factors which contributed to their change. the random and longitudinal data were combined with pedigree data to determine the effects of major genes, polygenes, and the environment on the variability of each apolipoprotein and on the relationship between these and other risk factors. an assessment was made in 100 individuals of the contribution of genetic variability at the dna level in determining apolipoprotein levels.

Eligibility criteria:
participation in prior survey of starr county, texas where 1,004 representative individuals of the population aged 15 and older were selected. the community was first mapped and random blocks selected. all individuals in households on selected blocks were enumerated and then 1 age eligible individual from each household was selected for a complete physical evaluation. from these, 250 individuals were identified as probands and their, primarily, first degree relatives were selected for the same examination. 1,254 individuals were seen in this phase. these individuals became eligible for the more complete profiling of apolipoproteins funded by the referenced grant.
study of standard maintenance method of intravenous port and post-operation pain analysis

Conditions: Cancer

Summary: investigators deconstructed the port that removed from patients and identified there were structural weakness, old blood clot and fibrin deposits. investigators consider the problem may be exist in maintenance. after thoroughly examination the maintenance protocol, investigators identified the problem and try to remodel the maintenance protocol. the goal of this study was to testify the clinical value of standard maintenance protocol.

a secure and easily feasible vascular access is crucial for oncology patients because of the therapeutic need. although intravenous port has been utilized for 3 decades, catheter-related complication still remain and had to deal with. according to investigators clinical experience, investigators summarized a standard algorithm as a recommendation for intravenous sport implantation. the complication before and after standard algorithm was 20 % and 3.5 %, respectively. however, catheter related infection and malfunction still could not be avoided. if patient was identified with these 2 complications, re-intervention is needed and cancer-related therapy has to be postpone. investigators deconstructed the port that removed from patients and identified there were structural weakness, old blood clot and fibrin deposits. investigators consider the problem may be exist in maintenance. after thoroughly examination the maintenance protocol, investigators identified the problem and try to remodel the maintenance protocol. the goal of this study was to testify the clinical value of standard maintenance protocol.

Eligibility criteria:
inclusion criteria: * volunteer with new port-a inserted exclusion criteria: * no

Keywords: intravenous port port maintenancem
comparative study between nebulised dexmedetomidine and nebulised midazolam in children undergoing lower abdominal surgeries

Conditions: Emergence Delirium; Anxiety Preoperative

Summary: comparative study between nebulised dexmedetomidine and nebulized midazolam in reducing preoperative anxiety and emergence delirium in children undergoing lower abdominal surgeries

dexmedetomidine is widely used in children and is replacing midazolam as the drug of choice for preoperative anxiolysis and sedation. however, there are limited studies comparing nebulized route in reducing preoperative anxiety and emergence delirium in children undergoing lower abdominal surgeries

Eligibility criteria:
inclusion criteria: * children aged 3-8 years * asa i\&ii * undergoing lower abdominal surgeries for example hernia repair and circumcision exclusion criteria: * children with chest infection, respiratory disease, cardiac disease * children with mental or physical disabilities, treatment with sedatives and anticonvulsants * parental refusal * allergy to study drugs
vital sensor monitors for cv19 detection

Conditions: Covid19

Summary: this study will monitor physical bio-markers such as heart rate, respiratory rate, and temperature to detect potential covid-19 infections.

the purpose of this research is to assess the accuracy of wearable sensors at detecting and monitoring covid-19 infections. our small, wearable sensor can get data on your respiration, body temperature, heart rate, and blood oxygen level, which may help physicians better identify if a respiratory condition is worsening overtime. if successful, our sensor could help healthcare professionals detect early symptoms of covid-19 respiratory infection and monitor recovery and treat people before their condition worsens significantly.

Eligibility criteria:
inclusion criteria: * adults aged 18 years old or over * recent (within 1 week) occupational or home exposure to a newly diagnosed covid-19 infected individual * able and willing to give written consent and comply with study procedures exclusion criteria: * inability to understand instructions and follow a three step command * the subject is pregnant, nursing or planning a pregnancy * inability to provide written consent * past confirmed covid-19 infection with resolution of symptoms * past confirmed covid-19 active infection moderate or severe symptoms
study of lapatinib in combination with paclitaxel in the treatment of newly diagnosed inflammatory breast cancer

Conditions: Neoplasms, Breast

Summary: this study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer. tumor tissue collected pre-treatment, following 14 days of treatment and at the time of surgical resection will be examined for pathologic response and biologic activity by ihc (immunohistochemistry) within the tumor. treatment will consist of 14 days of lapatinib monotherapy followed by 12 weeks of combination therapy with lapatinib and paclitaxel. blood samples for hematology and chemistry panels, muga/echo exams and physical exams will be performed throughout the study to monitor safety.


Eligibility criteria:
inclusion criteria: * tumor accessible for multiple biopsies * ecog (eastern cooperative oncology group) performance status 0-2 * adequate bone marrow * renal and hepatic function * lvef (left ventricular ejection fraction) greater than 0% based on echo (echocardiogram) or muga (multigated acquisition). exclusion criteria: * females who are pregnant or nursing. * any unstable, pre-existing major medical condition. * received an investigational drug within the past 4 weeks. * had major surgery in the past 2 weeks. * currently receiving amiodarone or has received amiodarone in the past 6 months.

Keywords: breast cancer
violence against health care workers in fragile settings

Conditions: Workplace Violence

Summary: the general objective of the project is to assess whether a violence de-escalating training for health professionals and of a publicly displayed code of conduct (a set of rules developed through a citizen science and co-design approach) for both health professionals and clients at the level of the health facility, can reduce the incidence and severity of episodes of violence, and to identify the most cost-effective way to implement these interventions in rural democratic republic of congo (drc) and in the mega city of baghdad, iraq.

the study will adopt a stepped-wedge cluster-randomized intervention trial (sw-crt) design to assess the two intervention components, a violence de-escalating training and the implementation of the code of conduct co-developed during the formative qualitative phase. the study will adopt a closed cohort with repeated measurements on the same participants (nurses in drc and junior doctors in baghdad) and will involve the unidirectional transition of each enrolled cluster (health facilities in drc and secondary hospitals in baghdad) from the control (no intervention) to the intervention sequence in a randomized sequential manner according to a predefined roll out process.

Eligibility criteria:
inclusion criteria: * hcws from selected participating health facilities in drc, junior doctors during their first year resident and permanent health care staff from participating secondary hospitals in iraq * hcws and junior medical doctors and permanent health care staff must have been employed/ or worked as hcw/ medical doctors or as permanent health care staff for at least 6 months * all above participants must have completed the written informed consent exclusion criteria: * age \<18 years; cognitive impairment

Keywords: de-escalating violence prevention behavioral symptoms code of conduct